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13 Glial Cell Extracellular Matrix in Alzheimer's Disease 
David A. DeWitt, David R. Canning, 
Jerry Silver 
and 
George Perry 
ABSTR...o\CT 
Many studies have yielded conflicting results regardi~g the toxic~ty of ~[3, 
the peptide which is the principal coml?on~nt <:,f senile. pla~ues III brams 
of patients with Alzheimer's disease. Usmg m mtra and zn ~zvo models, ~e 
have studied the role of glial cells and extracellular matnx molecules m 
mediating the effects of A[3. Glial cells respond to A[3 substrate by 
accumulating and depositing chondroitin sulfate proteoglycans (CSPGs) 
which are inhibitory to neurite outgrowth. CSPGs are present around the 
senile plaque core, an area with both dystrophic neurites an~ a general 
decrease in normal neurites. We suggest that CSPG may contnbute to the 
pathology by leading to regenerative failure of neurites surrounding 
senile plaques. 
ASTROCYTIC REACTION TO BRAIN INJURY 
Generalized Gliosis 
Classical observations by Cajal in the early part of this century described 
the changes associated with astrocytes following trauma and diseases of 
the CNS.1 This became known as gliosis and can be defined as the 
158 
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response of glia to local injury with a characteristic change in 
morphology of the responding cells. Such reactive cells assume ramified 
. . 23 
processes and develop pronounced hypertrophy and hyperplasIa. ' 
However, astrocytic response to injury· is somewhat heterogeneous. For 
instance, following a penetrating injury to the cerebral cortex, astrocytes 
proximal and distal to the lesion demonstrate elevated levels of glial 
fibrillary acidic protein and therefore are defined as gliotic.4 However, 
astrocytes closer to the site of injury are phenotypically different to those 
that are more distaL Astrocytes surrounding a penetrating injury in the 
cortex exhibit hyperplasia as well as hypertrophy, whereas astrocytes away 
from the injury site show almost exclusively hypertrophy.5,6 Moreover, it 
has been shown that only the astrocytes surrounding the actual injury site 
express vimentin, and markers which suggest these cells are undergoing 
localized proliferation.6 
It is generally believed that reactive gliosis is the main impediment to 
the regenerative efforts of the adult mammalian CNS.7 Such a view is 
supported by the experiments of Aguayo and collaborators who 
demonstrated. that mature neurons of the CNS retain the ability to 
regrow so long as the environment contains elements which provide a 
favorable substrate and support the growth of neuronal processes. 
However, outgrowth will not occur if the environment presented to the 
regenerating axonal process is non-permissive or contains actively 
inhibitory elements. In such a way, regenerating CNS neurons can 
extend a..xons into the regeneration-promoting areas of peripheral nerve 
grafts, but fail to penetrate into the regions where reactive gliosis forms 
a glial scar.8- 12 
Production of ECM Proteins 
While it is established that the cells and matrices of glial scars represent 
a barrier to axon regeneration, it is still controversial whether it is the 
cells themselves or molecules of the extracellular matrix which prevent 
process outgrowth. Glial scars13 consist of a dense meshwork of 
hypertrophied astrocytic processes and their associated molecular 
matrices13- 15 which together present a tortuous path for migrating 
growth cones. Although the physical presence of the glial scar creates a 
mechanical barrier that limits axon growth, changes in the molecular 
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properties of reactive astrocytes associated with a scar could also 
contribute to regenerative failure. 16 A decrease in growth promoting 
moleculesl7,lB or a local upregulation of axon inhibitory molecules by 
glia 19 could also diminish regeneration. Many molecules of the 
extracellular matrix play important roles during development of the 
nervous system and in homeostatic control of the CNS.20,21 Synthesis and 
modification of extracellular matrix components by reactive glial cells 
may be one of the most important features of the response of the CNS 
to injury and disease. 
Astrocytes respond to wounds in the central nervous system by the 
production of growth factors and various ECM proteins. In addition, 
microglia, in regions of neurodegeneration, secrete IL_122 which can 
induce TGF~ production and possibly ECM accumulation by astrocytes.23 
Tenascin and laminin are among several glycoproteins increased at 
wound sites_24 Laminin in particular is one of the most potent neurite 
outgrowth promoting molecules that exists. Tenascin can be both growth 
promoting or growth inhibiting depending on the presence of associated 
molecules.25 Even though the glial scar produces these and other factors 
that could encourage regeneration, nevertheless, it remains an obstacle 
to neurite outgrowth. Perhaps, the presence of growth inhibitory 
molecules can negate the facilitory effects of these factors. 
Many believe that astrocytes respond to mechanical wounds through 
the formation of a glial scar in order to re-establish a compromised glial 
limitans. Proteoglycans are a m"yor component of the gliallimitans and 
it has been demonstrated that proteoglycans are markedly increased in 
regions of reactive gliosis due to trauma.19,26,27 In vitro experiments have 
shown that proteoglycans can be potent inhibitors of neurite 
outgrowth.28,29 Thus, their enhanced presence in the glial scar could play 
a m,yor role in regenerative failure. This same kind of "walling off' 
response by astrocytes also appears to occur around SPs in AD. 
Glial Cells Associated with Senile Plaques in AD 
Senile plaques consist of a dense core of amyloid f)-protein (A[3), a 
40-42 amino acid peptide derived from a larger precursor, J3PP. 30 
Microglial cells are found throughout the senile plaque. The specific role 
of microglia is unknown although they might be responsible for AJ3 
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generation from J3PP. Others have suggested a more active role through 
the generation of complement attack complexes.3l Surrounding the AJ3 
core are many dystrophic neurites and processes of reactive astrocytes. 
Presumably, the cause of astrocyte reactivity is the extensive neuronal 
death which occurs throughout the AD brain or their reaction to A[3. 
However, a more active role for astrocytes has generally been 
overlooked32 and indeed, astrocytes could contribute to the pathology of 
the disease by altering the local environment to one that compromises 
neuronal viability. 
GLIAL REACTION TO AMYLOID 
J)-PROTEIN (AJ3) 
In Vitro Studies 
The fmding that AJ3 is normally produced and is found in a soluble 
.c 33 . 
10rm came as a surpnse to many researchers who viewed AJ3 as an 
unwanted, toxic, insoluble byproduct resulting from aberrant proteolysis. 
Therefore, the key event in SP formation may not be the generation of 
AJ3 per se, but rather factors that promote the accumulation of AJ3. The 
cellular responses to A~ are presently being defined and many 
conflicting studies have shown that A/3 is toxic or trophic to neurons 
depending on the experimental conditions.34,35 Much of the confusion 
of A/3 toxicity may be the result of parameters and factors other than A!3. 
AJ3 may not have a direct effect on neurons; instead, it may act indirectly 
by affecting other cells or ~ducing the accumulation of other molecules 
which are themselves harmful to neurons. Our approach has been to 
determine whether glial cells may be involved and whether molecules 
secondary to A~ may affect neurons. 
In an in vitro mode]36 A!3 is bound to specific areas on a tissue culture 
dish and used as a substrate for ceUs. Since AJ3 in the SPs is insoluble 
substrate bound A~ may simulate SP-AJ3 better than A!3 added to cultur~ 
media. Neurons show a preferential adherence to AJ3 and laminin 
together over laminin alone, corroborating another report suggesting 
that A!3 enhances the growth promoting activity oflaminin.37 Astrocytes, 
on the other hand, change morphology, become highly motile, and 
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Fig. 13.1 A. _!\.strocytes (arrows) grown on A{3 and lamin~n ~ubstrate 
accumulate and deposit chondroitin sulfate proteogly~an as mdlcated by 
fluorescent antibodies. B. Astrocytes infiltrate a mtrocellulose filter 
implanted in a neonatal rat. Here, the filter was coated with ~ prior to 
implantation. The astrocytes are immunoreactive for chondrOltm sulfate 
proteoglycan. 
eventually move off the A~ substrate. Astrocytes in contact with the Af3 
substrate accumulate CSPGs and deposit them on the substrate. When 
astrocytes are allowed to "precondition" the Af3 subs~ra~e ~~. CSPG, the 
substrate becomes inhibitory to neurite growth. This mhlbluon can be 
removed by digestion with chondroitinase, an en~~ :v~ch degra~es 
chondroitin glycosaminoglycan chains. Therefore, mhlbluon of neurIte 
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outgro-wth is correlated with the presence of CSPG as demonstrated in 
other systems.19,28,29 
In Vivo Studies 
Previous studies have examined the role of -A./3 injected into the brains of 
animals.35 Some have found neurodegeneration while others have not, 
further confounding the controversy of Af3 toxicity. One of the 
difficulties in interpreting such data is the variable amount of trauma 
which results from minor differences in the penetrating wounds. While 
one group found that Af3 injection with proteoglycans yielded fibrillar Af3 
which persisted, clear neurodegeneration due to Af3 remains 
questionable in view of the compounding effects of trauma and the 
formation of a glial scar. 38 
In one model of glial scarring, nitrocellulose filter implants are 
inserted into rat cortex. Astrocytes infiltrate the filter, and become 
intensely GFAP-positive.1 6 If the injury was made in an adult animal, 
these astrocytes accumulated CSPG which inhibits neurite outgrowth.19 
In a neonatal animal on the other hand, astrocytes infiltrate the filter, 
are GFAP-positive, but do not accumulate CSPG. Further, in the young 
animal, neurite outgrowth is possible and there is no glial scar formed. 
Since neonatal animals have astrocytic reaction without all of the 
characteristics of trauma, we implanted filters which were coated with Af3 
to determine the response of these cells. In the presence of A{3, neonatal 
astrocytes accumulate CSPG much the same as in the adult animal. While 
neurodegeneration was not observed in the young animal, it is 
interesting that Af3 causes young astrocytes to react as if they were adult. 
CSPGs have been shown to al;cumulate at sites of injury in the adult 
central nervous system. 19,27 While a variety of unknown triggers may be 
involved in the initiation and maintenance of reactive gliosis and CSPG 
accumulation, it appears that Af3 may be one such trigger. In the glial 
scar model of neonates, the presence of Af3 may accelerate, or amplify a 
normal cellular response. In the adult animal, it has been shown that ~PP 
is increased in response to injury.39 It is intriguing to consider the 
possibility that f3PP expression could yield Af3 which in turn induces 
CSPG at irdury sites. Therefore, one difference between the adult and 
young animal may be f3PP expression or processing. Exogenous Af3 in the 
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neonate may overcome any difference in J3PP and result in the same 
response of the adult, namely CSPG accumulation. This "normal" 
response could be increased or more pronounced with aging, thus 
explaining the presence of CSPG in adult wounds without exogenous AJ3. 
Astrocytes in Several N eurodegenera1ive Diseases 
Contain CSPG 
As noted earlier, many neurodegenerative diseases display reactive glia as 
an aspect of the pathology. Previously, we demonstrated that GFAP 
positive astrocytes in cases of Alzheimer's disease also contain CSPG.36,40 
The colocalization is especially noticed in the vicinity of SPs, consistent 
with in vitro and in vivo models of CSPG deposition upon an insoluble AJ3 
substrate. This observation suggests that AJ3 may be responsible for the 
accumulation of CSPG. We wanted to determine whether CSPG 
accumulation by reactive astrocytes is specific to Alzheimer's disease, or 
if it is common to other conditions of gliosis. 
Recently, we demonstrated that reacting astrocytes in several 
neurodegenerative diseases contain CSPG.41 While the study focused on 
diseases characterized by neuronal inclusions such as Parkinson's disease, 
Pick's disease, diffuse Lewy body disease, and progressive supranuclear 
palsy, we also examined cases of Huntington's di$ease. None of these 
diseases are charactierized by SPs or Aj3 deposition; however, all of them 
have CSPG-positive astrocytes. Of particular interest was Huntington's 
disease, which has CSPG-containing astrocytes in the basal gangalia but 
not in the cortex, suggesting astrocytic CSPG is associated with 
neurodegeneration. 
",,',lhiIe Af3 may playa key role in CSPG deposition in AD, there may be 
other initiators for CSPG accumulation during neurodegeneration. An 
important difference between astrocytic CSPG accumulation in AD and 
the other neurodegenerative diseases may be deposition. CSPG 
immunoreactivity in the other diseases is confmed to the astrocyte itself 
and may represent an internal accumulation or accumulation very close 
to the surface of the cell. In AD, on the other hand, CSPG is deposited 
around the SPs. This corresponds with the in vitro model which indicates 
that Aj3 induces CSPG accumulation and deposition. The release and 
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deposition of CSPG may have significant impact on the neuronal 
environment in the periphery of senile plaques. 
ENVIRONMENT OF TIIE SEN1LE PLAQUE 
PERIPHERY 
Rxtracellular Matrix Proteins Associated with Senile 
Plaques of Alzheimer's Disease 
Increases in specific glycosaminoglycans were initially reported in 
extracts made from the brains of Alzheimer's disease patients.42 Later, 
use of cationic dyes such as Alcian blue showed that glycosaminoglycans 
are associated with senile plaques (SP). 43 Further experimental 
approaches using a basic fibroblast grotvth factor (bFGF) binding assay 
indicates heparan sulfate proteoglycans (HSPG) in amyloid deposits, 
dystrophic neurites around SPs and extracellular NFTs. 44,45 
Immunocytochemical experiments indicate that the HSPG in SPs may be 
perle can, the basement membrane HSPG. 46 Chondroitin sulfate 
proteoglycans show a different distribution than HSPG.40 vVhile HSPG is 
found throughout the SP, CSPG is found only in the periphery, 
surrounding the Aj3 core. CSPG is also present in intracellular NFTs and 
dystrophic neurites as well as reactive astrocytes in the vicinity of senile 
plaques.36 Dermatan sulfate proteoglycan is also present in the SP 
periphery.47 
In addition to proteoglycans, several other ECM proteins are found in 
SPs including fibronectin,48 laminin,49 and collagen type IV.49 These 
ECM molecules are neurite outgrmv1:h promoting molecules, and were 
hypothesized to promote neurite outgrowth and sprouting in the SP. 
Indeed, several studies report increased and aberrant sprouting of 
neurites in SPs. These findings support the idea of trophic effects of Aj3 
and localization of growth factors in the SP. 
ECM-related molecules are also present in SPs including proteases and 
protease inhibitors that are involved in the degradation and protection 
of ECM molecules. al-antichymotrypsin, al-antitrypsin, anti-thrombin 
III, protease nexin I, and other protease inhibitors have been 
identified.50 Proteases including trypsin,51 chymotrypsin, 52 and 
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Fig. 13.2 A. bFGF binds to heparanase sensitive sites in senile plaques of 
Alzheimer's disease. B. Chondroitin 6-sulfate proteoglycan is found in 
the periphery, surrounding the Aj3 core. 
metalloprotease 953 have also been localized to SP. One recent 
hypothesis suggests that a proteolytic imbalance occurs in the area of a 
SP.54 The accumulation of ECM proteins in SPs might be the result of 
decreased matrix turnover. Indeed, the presence of TGF~55 in SPs could 
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upregulate ECM molecules and protease inhibitors, while down-
regulating matrix proteases. 
Degenerating Neurites 
Surrounding the A~ core of the SP are swollen, tortuous neuronal 
processes called dystrophic neurites. These neurites contain 1:,56 
ubiquitin,57 and show an accumulation of ~PP,58,59 the precursor protein 
which generates A~. The exact cause of neuritic dystrophy is unknown; 
however, it seems likely that a factor or event in the senile plaque is 
responsible, since these lesions are focal. It has long been hypothesized 
that A~ itself is the cause of neuritic dystrophy; however, numerous 
studies have called this hypothesis into question especially in light of the 
AJ3 toxic/trophic debate. 
The area surrounding SPs has been shoVl'!l to lack normal neurites.60 
Using neurofilament antibodies, Benes60 demonstrated that the density 
of normal neurites was reduced around SPs. Reduced neurite density 
occurred not only in the A~ core as would be expected but also up to twO 
plaque core distances away. Surprisingly, some normal neurites curve 
around the SP periphery. This suggests that the SP environment, in 
addition to causing neuritic dystrophy, may somehow prevent or reduce 
normal neurites in this area. 
Neuronal Sprouting? 
Another hypothesis for the cause of neuritic dystrophy is aberrant 
sprouting of neurons.61 Many growth factors and growth promoting 
molecules have been found in SPs including bFGF,62 laminin and 
collagen. Growth associated proteins such as GAP4363 and NTP64 have 
been identified in neurites of SPs. \-Vhile it has been suggested that 
excessive or abnormal sprouting of neurites due to increased trophism 
may cause neuritic dystrophy, the relation of these molecules to 
regeneration has not been overlooked. 55 Indeed, GAP43 and the other 
growth promoting/associated molecules are all characteristic of wound 
or regeneration related molecules. 
This suggests a different view of the neurites and ECM proteins in SPs. 
Instead of a growth promoting, trophic environment for excessive 
neurite outgrowth, the SP may prevent the restoration of synapses by 
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inhibiting neuritic infiltration into the area. Such an idea is supported by 
the bulbous, dystrophic neurites found in A~ deposits of AD brain which 
differ from degenerating neurites found in other neurological 
conditions66 and are not characterized by large, focal, extracellular 
deposits of wound related molecules_ 
Why is there a Halo? 
Further evidence suggests that the periphery around the SP, rather than 
the core itself, has the greatest impact on neurons. When retinal 
ganglion cells are grown on cryostat sections of AD brain67 they attach 
and put forth processes. No difference in the density of neurons which 
attach to SP cores and those which attach to areas lacking SPs is noted. 
However, the number which adhere to the periphery of SPs was 
substantially decreased. In addition, grow-th in this peri-plaque region is 
inhibited and neurons are more likely to extend a process away rather 
than toward SPs. Some neurons were obseIVed which initially grow 
toward a SP but then CUIVe and turn away. These results are consistent 
with the observations of a lack of normal neurites in the periphery of SPs. 
As neurons die throughout the brain in AD, there may be an attempt 
to recover some of the lost synapses through collateral sprouting. 
Astrocytic deposition of CSPG may impact this process by inhibiting 
neurite outgrowth, thus preventing the sprouts from reaching their 
potential targets. Therefore, while the number of synapses, neurons, and 
neurite density decreases throughout the brain in AD, attempts at 
recovery are possible except in the area of the periphery of the SP where 
CSPG prevents neuritic outgrowth as well as synaptic restoration. Synapse 
loss is accentuated in SPs, but not in diffuse SPs where there is no 
distinction from the rest of the neuropil.68 Interestingly, diffuse SPs do 
not have CSPG accumulation. Therefore, the presence of CSPG is 
correlated with increased synaptic pathology in the AD brain. 
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14 Role of Inflammation and 
Complement Activation in 
Alzheimer's Disease 
R. Veerhuis, 5.-5. Zhan 
and 
P. Eikelenboom 
ABSTRACT 
A variety of inflammatOry proteins has been identified, particularly in the 
vicinity of /3-amyloid plaques, in the brain of patients INith Alzheimer's 
disease. Current findings indicate that these molecules are involved in a 
num?er of key steps in the parbological cascade. Activation products of 
ClasSICal complement pathway Clq, C4 and C3, but not the alternative 
pathway factor properdin, have been demonstrated in diffuse and 
classical plaques. In addition, complement receptors (CR3 and CR4) 
bearing cells are found within classical plaques. There are contradictory 
findings about the question whether or not the late complement proteins 
that can form the membrane attack complex, are present in Alzheimer's 
disease brains. 
In this chapter we review the findings indicating that complement 
activation in amyloid plaques does not proceed further than C3. The idea 
is discussed that in Alzheimer's disease, complement does not function as 
an inflammatory mediator through membrane attack complex formation, 
but through the action of early complement activation products. 
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